Duesseldorf, October 8, 2019—Based on its good business results, Gerresheimer AG has increased its syndicated loan relative to the previous agreement by another EUR 100.0m, from EUR 450.0m to EUR 550.0m, while simultaneously further improving the conditions. Gerresheimer expects a long-term reduction in financing costs by some EUR 1m per year.
Once again, the proposed facility amount was substantially oversubscribed. The facility has a term of five years plus two extension options of one year each. It is arranged in the form of a revolving credit facility. “Based on our successful business results, we have succeeded in leveraging the favorable market conditions to extend our financial headroom for the long-term and improve the conditions under the facility documentation. This provides us with a stable foundation for continuing to systematically advance our business objectives,” commented Dr. Bernd Metzner, CFO of Gerresheimer AG.
About Gerresheimer
Gerresheimer is a leading global partner to the pharma and healthcare industries. The company’s special glass and plastic products contribute to health and well-being. Gerresheimer is a global organization with about 10,000 employees and manufacturing operations in the local markets, close to customers. With plants in Europe, North and South America and Asia Gerresheimer generates revenues of approximately EUR 1.4 billion. The comprehensive product portfolio includes pharmaceutical packaging products as well as convenient and safe drug delivery systems such as insulin pens, inhalers, micro pumps, prefillable syringes, vials, ampoules, bottles and containers for liquid and solid pharmaceuticals with closure and safety systems, plus cosmetic packaging products.
